Quince Therapeutics Q2 net loss widens on acquisition charges

IRulya Therapeutics

14/08/2026 13:18

Overview
US biopharmaceutical developer completed Orphai acquisition, adding LAM-001 to late-stage pulmonary pipeline
Company closed $115 mln private placement financing, boosting cash to $116 mln as of June 30, 2026
Q2 net loss widened due to acquisition-related charges and increased G&A expenses

Outlook
Quince expects Phase 2 data for LAM-001 in BOS in Q1 2027
Phase 2b data for LAM-001 in PH-ILD anticipated in Q1 2028
Company expects cash position to fund operations through end of 2028

Result Drivers
ACQUISITION-RELATED CHARGES - Net loss increased due to one-time charges from the Orphai acquisition and assumption of historical options
PIPELINE EXPANSION - Acquisition of Orphai added LAM-001, advancing late-stage pulmonary disease programs
R&D SPENDING SHIFT - Overall R&D expense fell as eDSP program wound down, while LAM-001 costs increased due to study start-up

Company press release: ID:nGNXK9nnK

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$12.31
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Quince Therapeutics, Inc. is $81.00, about 149.9% above its August 13 closing price of $32.41

Reuters Recommended Reads
Aug 12 - Liquidia Q2 revenue jumps on YUTREPIA sales
Aug 11 - Savara Q2 loss widens as operating expenses rise
Aug 13 - Pulmatrix Q2 loss narrows on clinical development hold

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)